Pfizer Inc (PFE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
682
About the Report
About the Report
Summary
Pfizer Inc (Pfizer) is a biopharmaceutical company, which discovers, develops, manufactures and markets healthcare products. It provides medicines, vaccines and consumer healthcare products. The company provides products to treat various conditions including infection, cancer, inflammation, immune disorders and rare diseases, besides vaccines. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells prescription medicines through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It sells consumer healthcare products through pharmacies, retail chains, distributors and grocery and convenience stores. The company provides its products in the North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
Pfizer Inc (PFE)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Pfizer Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 13
List of Figures 19
Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20
Pfizer Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21
Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22
Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23
Pfizer Inc, Medical Devices Deals, 2012 to YTD 2018 25
Pfizer Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 26
Pfizer Inc, Pharmaceuticals & Healthcare, Deal Details 50
Asset Purchase 50
Pfizer to Acquire Neksium Brand from AstraZeneca 50
Pfizer Acquires Small Molecule Anti-Infective Business from AstraZeneca 51
Pfizer Acquires Assets of BIND Therapeutics for USD40 Million 53
Bamboo Therapeutics Acquires Viral Gene Therapy Manufacturing Facility from University of North Carolina 54
Medivation Acquires Rights to Talazoparib from BioMarin Pharma 55
Pfizer Acquires Nimenrix and Mencevax from GlaxoSmithKline for USD130 Million 56
Bamboo Therapeutics Acquires Rights to Canavan Disease Proposed Drug from Rowan University 57
Pfizer Acquires Portfolio of Vaccines from Baxter for USD648 Million 58
Hospira Healthcare Completes Acquisition of Manufacturing and R&D Facility from Orchid Chemicals & Pharma for USD218 Million 60
Pfizer Acquires Melanocortin Receptors from MRC Technology 62
Pfizer Plans To Sell Certain Ohthalmology R&D Assets 63
Pfizer Completes Acquisition Of Polocard From Polpharma For USD 32 Million 64
Venture Financing 65
Morphic Therapeutic Raises USD80 Million in Series B Financing 65
Biodesy Raises USD20 Million in Series C Venture Financing 67
4D Molecular Therapeutics Raises USD90 Million in Series B Venture Financing 68
Artios Pharma Raises USD83.6 Million in Series B Venture Financing 70
Therachon Raises USD60 Million in Mezzanine Financing 72
Nimbus Therapeutics Raises USD65 Million in Financing 74
Cortexyme Raises USD76 Million in Series B Venture Financing 76
Strata Oncology Raises USD26 Million in Series B Venture Financing 78
Allogene Therapeutics to Raise USD300 Million in Series A Financing 80
Adapsyn Bioscience Raises Funds through Venture Financing 82
Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 83
Cydan Raises USD34 Million in Venture Financing 85
Palleon Pharma Raises USD47.6 Million in Series A Financing 86
SpringWorks Therapeutics Raises USD103 Million in Series A Financing 87
Complexa Raises USD62 Million in Series C Financing 89
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 90
Neuronetics Raises USD15 Million in Series G Round of Financing 92
Arrakis Therapeutics Raises USD38 Million in Series A Venture Financing 94
Rhythm Pharma Raises USD41 Million in Mezzanine Financing 96
Circle Pharma Raises Funds through Series A Preferred Stock Financing 98
Ixchelsis Raises Additional USD12 Million in Venture Financing 99
Vtesse Raises USD17 Million in Extended Series A Financing 100
Second Genome Raises USD8.4 Million in Extended Series B Financing 101
Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 102
Storm Therapeutics Raises USD16 Million in Series A Venture Financing 104
Blade Therapeutics Raises USD27 Million in Series B Financing 105
Second Genome Raises USD42.6 Million in Series B Financing 107
Cydan Development Raises USD31 Million in Series A Financing 109
Metabomed Raises USD18 Million in Series A Venture Financing 110
Mission Therapeutics Raises USD85.7 Million in Financing Round 111
Biodesy Raises USD10 Million in Series B Financing 112
Lodo Therapeutics Raises USD17 Million in Series A Financing 113
Bamboo Therapeutics Raises USD49.5 Million in Venture Financing 115
NextCure Raises USD67 Million in Series A Financing 116
Petra Pharma Raises USD48 Million in Series A Financing 118
Cortexyme Raises USD15 Million in Series A Financing Round 120
Merus Raises USD46.4 Million in First Tranche of Series C Financing 121
Rhythm Metabolic Raises USD40 Million in Series A Financing Round 123
Autifony Therapeutics Raises USD12.3 Million in Extended Series A Financing 125
Mirna Therapeutics Raises USD41.8 Million in Series D Financing 126
Nimbus Therapeutics Raises USD43 Million in Series B Financing 128
Mersana Therapeutics Raises USD35 Million in Series B Financing 130
Vtesse Raises USD25 Million in Series A Financing 131
CytomX Therapeutics Raises USD20 Million in Series C Venture Financing 132
Ziarco Raises USD33 Million in Series B Venture Financing 133
Quartet Medicine Raises USD17 Million in Series A Venture Financing 134
Circle Pharma Raises Funds through Seed Financing 135
Epic Sciences Raises USD30 Million in Series C Venture Financing 136
NexImmune Raises USD3 Million in Venture Financing 137
Mission Therapeutics Raises USD 32 Million In Series B Financing 138
Biodesy Raises USD 15 Million In Series A Financing 139
Merus Raises USD 42 Million In Extended Series B Financing 140
Cydan Raises USD 26 Million In Venture Financing 142
Esperion Therapeutics Raises USD 33 Million In Venture Financing 144
Aquinox Pharma Raises USD 18 Million In Series C Financing 146
Esperion Therapeutics Raises USD 1 Million In Venture Financing 147
Flexion Therapeutics Raises USD20 Million In Series B Financing 148
Rhythm Pharma Raises USD 33 Million In Series B Financing 149
Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 151
Epic Sciences Raises USD 13 Million In Series B Financing 153
Ziarco Pharma Raises USD 6 Million In First Tranche Of Series A financing 154
Mirna Therapeutics Raises USD 34 Million In Series C Financing 155
Mersana Therapeutics Raises USD 27 Million In Series A-1 Financing 157
InnoPharma Raises USD 8 Million In Venture Financing 159
Flexion Therapeutics Raises Additional USD 13 Million In Series A Financing 160
Celladon Raises Additional USD 10 Million In Series D Financing 161
Private Equity 163
Bain Capital May Acquire Laboratorio Teuto Brasileiro 163
Partnerships 164
Pfizer Enters into Licensing Agreement with Scripps Research Institute 164
Ichor Medical Systems Enters Into Licensing Agreement With Pfizer 165
Nektar Therapeutics Enters into Collaboration Agreement with Pfizer 166
Kyowa Hakko Kirin Enters into Agreement with Merck and Pfizer 167
Pfizer Enters into Co-Development Agreement with Novartis 168
Daiichi Sankyo Enters into Research Collaboration with Merck and Pfizer 169
Bain Capital and Pfizer Form Joint Venture 170
Myriad Genetics and Pfizer Enter into Agreement 171
Calithera Biosciences Enters into Partnership with Pfizer 172
Atomwise Enters into Evaluation Agreement with Pfizer 173
CYTOO Enters into Research and Option Agreement with Pfizer 174
Checkmate Pharma Enters into Partnership with Merck and Pfizer 175
BioNTech Enters into R&D Agreement with Pfizer 176
Leap Therapeutics Enters into Co-Development Agreement with Merck and Pfizer 177
Vyriad Enters into Collaboration Agreement with Merck and Pfizer 178
XtalPi Enters into Research Agreement with Pfizer 179
BioDuro Enters into Agreement with Pfizer 180
Neofluidics Enters into Agreement with Pfizer 181
NetVation DL Medicine Enters into Research Agreement with Pfizer 182
MindImmune Therapeutics Enters into Research Agreement with Pfizer 183
Kite Pharma Enters into Partnership with Pfizer 184
Adapsyn Bioscience Enters into Research Agreement with Pfizer 185
Array BioPharma Enters into Agreement with Pfizer 186
Encycle Therapeutics Enters into Research Agreement with Pfizer 187
Themis Medicare Forms Joint Venture Agreement with Global Pharmatech 188
University of Texas MD Anderson Cancer Center Enters into Partnership with Pfizer 189
Phosplatin Therapeutics Enters into Agreement with Pfizer and Merck 190
Alcyone Lifesciences Enters into Agreement with Pfizer 191
eFFECTOR Therapeutics Enters into Agreement with Merck and Pfizer 192
Astellas Pharma Amends Agreement with Pfizer 193
EpiThany Enters into Agreement with Merck and Pfizer 194
VAXIMM Enters into Agreement with Merck and Pfizer 195
Domain Therapeutics Enters into Partnership with Pfizer 196
Pfizer Enters into Agreement with Washington University in St. Louis 197
Edelris Enters into Research Agreement with Pfizer 198
AbCellera Biologics Enters into Research Agreement with Pfizer 199
Pfizer Partners with NovaMedica 200
PegBio Partners with Pfizer 201
Pfizer Enters into Agreement with National Cancer Institute 202
Debiopharm Partners with Merck and Pfizer 203
Transgene Enters into Agreement with Merck and Pfizer 204
Circle Pharma Partners with Pfizer 205
Pfizer and CR Saike Pharma Enter into Distribution Agreement 206
Pfizer Partners with inVentiv Health 207
Fuji Yakuhin and Pfizer Enter into Co-Promotion Agreement 208
BioRap Technologies Enters into Co- Development Agreement with Pfizer 209
Pfizer Enters into Agreement with NovaQuest Capital Management 210
Pierre Fabre Medicament Enters into Agreement with Pfizer for Toviaz 211
Merck, Pfizer and Verastem Enter into Agreement 212
Pfizer Enters into Partnership Agreement with RPI Finance Trust 213
Pfizer Enters into Agreement with California Institute for Biomedical Research 214
Pfizer Enters into Research Agreement with Adaptive Biotech 215
Merck, Pfizer and Syndax Pharma Enter into Agreement 216
Heptares Therapeutics Enters into Agreement with Pfizer 217
Pfizer Enters into Agreement with Biovac Institute 218
Pfizer Enters into Agreement with GlaxoSmithKline 219
Pfizer Enters into Agreement with Synthon 220
Centers for Therapeutic Innovation Enters into Research Agreement with Jeffrey Modell Foundation 221
CDC Foundation Enters into Agreement with Pfizer and Centers for Disease Control and Prevention 222
Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 223
Regimmune Enters into Research Agreement with JDRF and Pfizer 224
BIND Therapeutics Extends Global Agreement with Pfizer to Develop and Commercialize Multiple Accurins 225
HiFiBiO Enters into Research Agreement with Pfizer 226
Pharmacosmos Enters into Agreement with Pfizer 227
Alzheimer Drug Discovery Enters into Research Agreement with CTI for Alzheimer's Disease Drugs 228
University of Dundee Enters into Research Agreement with Pfizer 229
HemoShear Enters into Agreement with Pfizer 230
Pfizer Enters into Co-Development Agreement with Merck 231
Novartis Enters into Agreement with Pfizer to Commercialize Ultibro Breezhaler and Seebri Breezhaler 233
Crohn’s & Colitis Foundation of America and Pfizer Enter into Agreement for Inflammatory Bowel Disease 234
Anacor Pharma Amends Co-Marketing Agreement with Sandoz for Kerydin 235
X-Chem Enters into Co-Development Agreement with Pfizer 237
KineMed Extends Research Agreement with Pfizer for Metabolic Disease Therapies 238
Cambridge University, Imperial College London, King’s College London, Queen Mary University London, University College London and Oxford University Enter into Research and Development Agreement with Pfizer 239
EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 241
BioRestorative Therapies Enters into Research Agreement with Pfizer 242
Process Systems Enters Into Co-Development Agreement With Pfizer 243
Pfizer Enters Into Development Agreement With University of Texas MD Anderson Cancer Center For Cancer Immunotherapy 244
Octapharma Enters Into Co-Marketing Agreement With Pfizer 245
Protagen Enters Into Biomarker Discovery Agreement With Pfizer 246
Eli Lilly Enters Into Co-Development Agreement With Pfizer For Tanezumab 247
Joslin Diabetes Center Enters Into Co-Development Agreement With Pfizer And Lilly 248
Sanford-Burnham Medical Research Institute Enters Into Research Agreement With Pfizer 249
Pfizer Plans To Form Joint Ventures To Accelerate Drug Development 250
Centers For Therapeutic Innovation Partners with UC San Francisco 251
Merck Enters Into Co-Development Agreement With Pfizer For Ertugliflozin 252
Anacor Pharma Amends Research Agreement With Bill & Melinda Gates Foundation 253
Bind Therapeutics Enters Into Global Agreement With Pfizer To Develop And Commercialize Multiple Accurins 254
OxOnc Development Enters Into Co-Development Agreement With Pfizer For Crizotinib 255
Humedica Enters Into Agreement With Pfizer 257
AstraZeneca And Pfizer Partner With Government of Quebec To Develop Research Centre 258
Cystic Fibrosis Foundation Therapeutics Enters Into Research Agreement With Pfizer For Cystic Fibrosis Drugs 259
Apredica Enters Into Research Agreement With Pfizer 260
Mochida Pharma Enters Into Agreement With Hospira Japan To Distribute And Promote Oncology Products 261
Pfizer Forms Joint Venture With Zhejiang Hisun Pharma For Generic Medicines 262
Visterra Enters Into Agreement With Pfizer To Discover Novel Antibodies 263
SFJ Pharma Enters Into Co-Development Agreement With Pfizer For Dacomitinib 264
Pfizer To Enter Into Co-Development Agreement With Mylan For Generic Drugs 265
Nodality Enters Into Agreement With Pfizer For Single Cell Network Profiling Technology 266
Pfizer Enters Into Co-Development Agreement With Harvard University 267
Cold Spring Harbor Labs Enters Into Research Agreement With Pfizer For New Cancer Therapies 268
Ildong Pharma Enters Into Co-Promotion Agreement With Pfizer Pharma For Generic Drugs 269
Pfizer Extends Co-Promotion Agreement With Astellas Pharma For Lipitor 270
Pfizer Enters into Co-Promotion Agreement with Specpharm 271
Pfizer Plans To Enter Into Co-Development Agreement With India-Based Pharma Company 272
Pfizer Enters Into Co-Marketing Agreement With Biologics For Inlyta 273
KineMed Extends Research Agreement With Pfizer 274
ICM Enters into Research Collaboration with Pfizer 275
KineMed Enters Into Co-Development Agreement With Pfizer 276
SFJ Pharma Enters Into Co-Development Agreement With Pfizer 277
Licensing Agreements 278
Pfizer Enters into Licensing Agreement with Cancer Therapeutics CRC 278
Pfizer Amends Licensing Agreement with Spark Therapeutics 279
Allogene Therapeutics Enters into Licensing Agreement with Pfizer 281
Suzhou Kintor Pharma Enters into Licensing Agreement with Pfizer 282
Imcyse Research Agreement with Pfizer 283
Pfizer Enters into Licensing Agreement with Distributed Bio for SuperHuman Platform 284
Pfizer Enters into Licensing Agreement with Berkeley Lights 285
Sangamo Therapeutics Enters into Licensing Agreement with Pfizer 286
Pfizer Enters into Licensing Agreement with Arvinas 287
SpringWorks Therapeutics Receives Rights from Pfizer 288
Pfizer Amends Licensing Agreement with Basilea Pharma 289
Pfizer Enters into Licensing Agreement with Sangamo Therapeutics 290
Pfizer Enters into Licensing Agreement with HitGen 291
Absorption Systems Enters into Licensing Agreement with Pfizer 292
Pfizer Enters into Licensing Agreement with BioInvent International 293
Pfizer Enters into Licensing Agreement with Ab Initio Biotherapeutics 294
Pfizer Enters into Licensing Agreement with OncoImmune 295
Pfizer Enters into Option Agreement with AnTolRx 296
Pfizer Enters into Licensing Agreement with Western Oncolytics 297
Shire Enters into Licensing Agreement with Pfizer 298
Pfizer Inc - Key Competitors 499
Pfizer Inc - Key Employees 500
Pfizer Inc - Locations And Subsidiaries 502
Head Office 502
Other Locations & Subsidiaries 502
Joint Venture 525
Recent Developments 526
Strategy And Business Planning 526
Oct 30, 2018: Novartis and Pfizer partner to advance NASH therapy 526
Oct 24, 2018: Pfizer partners with Bain Capital to launch new CNS therapy firm 527
Jul 24, 2018: Pfizer to build $465m injectable medicines facility in US 528
Jul 11, 2018: Pfizer to split into three businesses 529
Jan 04, 2018: Jacobs Appointed as EPCM Contractor for New Gene Therapy Manufacturing Facility 530
Oct 10, 2017: Pfizer Reviewing Strategic Alternatives for Consumer Healthcare Business 531
Aug 07, 2017: Pfizer to Invest in Gene Therapy Manufacturing Facility in North Carolina 532
Jun 28, 2017: Pfizer breaks ground on new R&D facility in Missouri 534
Jun 27, 2017: Pfizer Breaks Ground on New R&D Facility in Chesterfield, Missouri 535
Mar 06, 2017: Pfizer Selects Turner & Townsend For Expansion Of Its Clinical Research Unit In Belgium 536
Financial Announcements 537
Jul 31, 2018: Pfizer reports second-quarter 2018 results 537
May 01, 2018: Pfizer Reports First-Quarter 2018 Results 542
Jan 30, 2018: Pfizer Reports Fourth-Quarter And Full-Year 2017 Results 546
Oct 31, 2017: Pfizer Reports Third-Quarter 2017 Results 553
Oct 30, 2017: Pfizer reports thirdquarter 2018 results 556
Aug 01, 2017: Pfizer Reports Second-Quarter 2017 Results 565
May 02, 2017: Pfizer Reports First-Quarter 2017 Results 569
Jan 31, 2017: Pfizer Reports Fourth-Quarter And Full-Year 2016 Results 573
Corporate Communications 578
Oct 09, 2018: Pfizer announces Executive Leadership Team 578
Oct 01, 2018: Pfizer announces CEO succession 579
Sep 18, 2018: Good Health and Well-Being : A Mission for Business and Society 581
Jun 12, 2018: Extending Antibiotic Donations to Eliminate Trachoma 582
Mar 05, 2018: Pfizer Names Dan R. Littman As Board Director 583
Feb 23, 2018: Pfizer Appoints Albert Bourla As Board Director 584
Jan 08, 2018: Pfizer Ends Alzheimer's and Parkinson's Disease Programs, to Eliminate 300 Jobs 585
Nov 13, 2017: Pfizer Names Albert Bourla Chief Operating Officer 586
Oct 04, 2017: AmerisourceBergen, Blue Cross Blue Shield Association, Pfizer and Prime Therapeutics Join Walgreens to Combat Prescription Drug Abuse by Expanding Safe Medication Disposal Program 588
Feb 23, 2017: Ronald E. Blaylock Elected to Pfizer’s Board of Directors 590
Legal and Regulatory 591
Jun 11, 2018: Pfizer wins appeal against CMA fine over epilepsy drug price 591
May 24, 2018: Drug Maker Pfizer Agrees to Pay $23.85 Million to Resolve False Claims Act Liability for Paying Kickbacks 592
Government and Public Interest 594
Oct 04, 2018: Pfizer to award more than 3 million in grants to further breast cancer research 594
Sep 04, 2018: Pfizer estimates $100M in supply chain costs for adapting to Brexit requirements 595
Jul 11, 2018: Pfizer reverses drug price hike after President Trump’s protests 596
Jun 08, 2018: GEA supports Pfizer to change from batch-based to continuous manufacturing 597
May 30, 2018: The Pfizer Foundation Announces $5 Million in Grants to Support Women and Families 598
Feb 02, 2018: BCRF Announces Expansion of the Drug Research Collaborative 599
Nov 20, 2017: NCCN, in Collaboration with Pfizer, Awards Nine Grants for Quality Improvement in Breast Cancer Care 600
Nov 16, 2017: Breast cancer patients to have routine access to two life extending drugs after new deal, say NICE in draft guidance 601
List of Figure
List of Figures
Pfizer Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20
Pfizer Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 21
Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22
Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 23
Pfizer Inc, Medical Devices Deals, 2012 to YTD 2018 25
List of Table
List of Tables
Pfizer Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 20
Pfizer Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 21
Pfizer Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 22
Pfizer Inc, Deals By Therapy Area, 2012 to YTD 2018 23
Pfizer Inc, Medical Devices Deals, 2012 to YTD 2018 25
Pfizer Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 26
Pfizer to Acquire Neksium Brand from AstraZeneca 50
Pfizer Acquires Small Molecule Anti-Infective Business from AstraZeneca 51
Pfizer Acquires Assets of BIND Therapeutics for USD40 Million 53
Bamboo Therapeutics Acquires Viral Gene Therapy Manufacturing Facility from University of North Carolina 54
Medivation Acquires Rights to Talazoparib from BioMarin Pharma 55
Pfizer Acquires Nimenrix and Mencevax from GlaxoSmithKline for USD130 Million 56
Bamboo Therapeutics Acquires Rights to Canavan Disease Proposed Drug from Rowan University 57
Pfizer Acquires Portfolio of Vaccines from Baxter for USD648 Million 58
Hospira Healthcare Completes Acquisition of Manufacturing and R&D Facility from Orchid Chemicals & Pharma for USD218 Million 60
Pfizer Acquires Melanocortin Receptors from MRC Technology 62
Pfizer Plans To Sell Certain Ohthalmology R&D Assets 63
Pfizer Completes Acquisition Of Polocard From Polpharma For USD 32 Million 64
Morphic Therapeutic Raises USD80 Million in Series B Financing 65
Biodesy Raises USD20 Million in Series C Venture Financing 67
4D Molecular Therapeutics Raises USD90 Million in Series B Venture Financing 68
Artios Pharma Raises USD83.6 Million in Series B Venture Financing 70
Therachon Raises USD60 Million in Mezzanine Financing 72
Nimbus Therapeutics Raises USD65 Million in Financing 74
Cortexyme Raises USD76 Million in Series B Venture Financing 76
Strata Oncology Raises USD26 Million in Series B Venture Financing 78
Allogene Therapeutics to Raise USD300 Million in Series A Financing 80
Adapsyn Bioscience Raises Funds through Venture Financing 82
Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 83
Cydan Raises USD34 Million in Venture Financing 85
Palleon Pharma Raises USD47.6 Million in Series A Financing 86
SpringWorks Therapeutics Raises USD103 Million in Series A Financing 87
Complexa Raises USD62 Million in Series C Financing 89
eFFECTOR Therapeutics Raises USD38.6 Million in Series C Financing 90
Neuronetics Raises USD15 Million in Series G Round of Financing 92
Arrakis Therapeutics Raises USD38 Million in Series A Venture Financing 94
Rhythm Pharma Raises USD41 Million in Mezzanine Financing 96
Circle Pharma Raises Funds through Series A Preferred Stock Financing 98
Ixchelsis Raises Additional USD12 Million in Venture Financing 99
Vtesse Raises USD17 Million in Extended Series A Financing 100
Second Genome Raises USD8.4 Million in Extended Series B Financing 101
Morphic Therapeutic Raises USD51.5 Million in Series A Venture Financing 102
Storm Therapeutics Raises USD16 Million in Series A Venture Financing 104
Blade Therapeutics Raises USD27 Million in Series B Financing 105
Second Genome Raises USD42.6 Million in Series B Financing 107
Cydan Development Raises USD31 Million in Series A Financing 109
Metabomed Raises USD18 Million in Series A Venture Financing 110
Mission Therapeutics Raises USD85.7 Million in Financing Round 111
Biodesy Raises USD10 Million in Series B Financing 112
Lodo Therapeutics Raises USD17 Million in Series A Financing 113
Bamboo Therapeutics Raises USD49.5 Million in Venture Financing 115
NextCure Raises USD67 Million in Series A Financing 116
Petra Pharma Raises USD48 Million in Series A Financing 118
Cortexyme Raises USD15 Million in Series A Financing Round 120
Merus Raises USD46.4 Million in First Tranche of Series C Financing 121
Rhythm Metabolic Raises USD40 Million in Series A Financing Round 123
Autifony Therapeutics Raises USD12.3 Million in Extended Series A Financing 125
Mirna Therapeutics Raises USD41.8 Million in Series D Financing 126
Nimbus Therapeutics Raises USD43 Million in Series B Financing 128
Mersana Therapeutics Raises USD35 Million in Series B Financing 130
Vtesse Raises USD25 Million in Series A Financing 131
CytomX Therapeutics Raises USD20 Million in Series C Venture Financing 132
Ziarco Raises USD33 Million in Series B Venture Financing 133
Quartet Medicine Raises USD17 Million in Series A Venture Financing 134
Circle Pharma Raises Funds through Seed Financing 135
Epic Sciences Raises USD30 Million in Series C Venture Financing 136
NexImmune Raises USD3 Million in Venture Financing 137
Mission Therapeutics Raises USD 32 Million In Series B Financing 138
Biodesy Raises USD 15 Million In Series A Financing 139
Merus Raises USD 42 Million In Extended Series B Financing 140
Cydan Raises USD 26 Million In Venture Financing 142
Esperion Therapeutics Raises USD 33 Million In Venture Financing 144
Aquinox Pharma Raises USD 18 Million In Series C Financing 146
Esperion Therapeutics Raises USD 1 Million In Venture Financing 147
Flexion Therapeutics Raises USD20 Million In Series B Financing 148
Rhythm Pharma Raises USD 33 Million In Series B Financing 149
Motus Therapeutics Secures Additional USD8 Million in Series B Round of Venture Funding 151
Epic Sciences Raises USD 13 Million In Series B Financing 153
Ziarco Pharma Raises USD 6 Million In First Tranche Of Series A financing 154
Mirna Therapeutics Raises USD 34 Million In Series C Financing 155
Mersana Therapeutics Raises USD 27 Million In Series A-1 Financing 157
InnoPharma Raises USD 8 Million In Venture Financing 159
Flexion Therapeutics Raises Additional USD 13 Million In Series A Financing 160
Celladon Raises Additional USD 10 Million In Series D Financing 161
Bain Capital May Acquire Laboratorio Teuto Brasileiro 163
Pfizer Enters into Licensing Agreement with Scripps Research Institute 164
Ichor Medical Systems Enters Into Licensing Agreement With Pfizer 165
Nektar Therapeutics Enters into Collaboration Agreement with Pfizer 166
Kyowa Hakko Kirin Enters into Agreement with Merck and Pfizer 167
Pfizer Enters into Co-Development Agreement with Novartis 168
Daiichi Sankyo Enters into Research Collaboration with Merck and Pfizer 169
Bain Capital and Pfizer Form Joint Venture 170
Myriad Genetics and Pfizer Enter into Agreement 171
Calithera Biosciences Enters into Partnership with Pfizer 172
Atomwise Enters into Evaluation Agreement with Pfizer 173
CYTOO Enters into Research and Option Agreement with Pfizer 174
Checkmate Pharma Enters into Partnership with Merck and Pfizer 175
BioNTech Enters into R&D Agreement with Pfizer 176
Leap Therapeutics Enters into Co-Development Agreement with Merck and Pfizer 177
Vyriad Enters into Collaboration Agreement with Merck and Pfizer 178
XtalPi Enters into Research Agreement with Pfizer 179
BioDuro Enters into Agreement with Pfizer 180
Neofluidics Enters into Agreement with Pfizer 181
NetVation DL Medicine Enters into Research Agreement with Pfizer 182
MindImmune Therapeutics Enters into Research Agreement with Pfizer 183
Kite Pharma Enters into Partnership with Pfizer 184
Adapsyn Bioscience Enters into Research Agreement with Pfizer 185
Array BioPharma Enters into Agreement with Pfizer 186
Encycle Therapeutics Enters into Research Agreement with Pfizer 187
Themis Medicare Forms Joint Venture Agreement with Global Pharmatech 188
University of Texas MD Anderson Cancer Center Enters into Partnership with Pfizer 189
Phosplatin Therapeutics Enters into Agreement with Pfizer and Merck 190
Alcyone Lifesciences Enters into Agreement with Pfizer 191
eFFECTOR Therapeutics Enters into Agreement with Merck and Pfizer 192
Astellas Pharma Amends Agreement with Pfizer 193
EpiThany Enters into Agreement with Merck and Pfizer 194
VAXIMM Enters into Agreement with Merck and Pfizer 195
Domain Therapeutics Enters into Partnership with Pfizer 196
Pfizer Enters into Agreement with Washington University in St. Louis 197
Edelris Enters into Research Agreement with Pfizer 198
AbCellera Biologics Enters into Research Agreement with Pfizer 199
Pfizer Partners with NovaMedica 200
PegBio Partners with Pfizer 201
Pfizer Enters into Agreement with National Cancer Institute 202
Debiopharm Partners with Merck and Pfizer 203
Transgene Enters into Agreement with Merck and Pfizer 204
Circle Pharma Partners with Pfizer 205
Pfizer and CR Saike Pharma Enter into Distribution Agreement 206
Pfizer Partners with inVentiv Health 207
Fuji Yakuhin and Pfizer Enter into Co-Promotion Agreement 208
BioRap Technologies Enters into Co- Development Agreement with Pfizer 209
Pfizer Enters into Agreement with NovaQuest Capital Management 210
Pierre Fabre Medicament Enters into Agreement with Pfizer for Toviaz 211
Merck, Pfizer and Verastem Enter into Agreement 212
Pfizer Enters into Partnership Agreement with RPI Finance Trust 213
Pfizer Enters into Agreement with California Institute for Biomedical Research 214
Pfizer Enters into Research Agreement with Adaptive Biotech 215
Merck, Pfizer and Syndax Pharma Enter into Agreement 216
Heptares Therapeutics Enters into Agreement with Pfizer 217
Pfizer Enters into Agreement with Biovac Institute 218
Pfizer Enters into Agreement with GlaxoSmithKline 219
Pfizer Enters into Agreement with Synthon 220
Centers for Therapeutic Innovation Enters into Research Agreement with Jeffrey Modell Foundation 221
CDC Foundation Enters into Agreement with Pfizer and Centers for Disease Control and Prevention 222
Merck Enters into Co-Promotion Agreement with Pfizer for XALKORI 223
Regimmune Enters into Research Agreement with JDRF and Pfizer 224
BIND Therapeutics Extends Global Agreement with Pfizer to Develop and Commercialize Multiple Accurins 225
HiFiBiO Enters into Research Agreement with Pfizer 226
Pharmacosmos Enters into Agreement with Pfizer 227
Alzheimer Drug Discovery Enters into Research Agreement with CTI for Alzheimer's Disease Drugs 228
University of Dundee Enters into Research Agreement with Pfizer 229
HemoShear Enters into Agreement with Pfizer 230
Pfizer Enters into Co-Development Agreement with Merck 231
Novartis Enters into Agreement with Pfizer to Commercialize Ultibro Breezhaler and Seebri Breezhaler 233
Crohn’s & Colitis Foundation of America and Pfizer Enter into Agreement for Inflammatory Bowel Disease 234
Anacor Pharma Amends Co-Marketing Agreement with Sandoz for Kerydin 235
X-Chem Enters into Co-Development Agreement with Pfizer 237
KineMed Extends Research Agreement with Pfizer for Metabolic Disease Therapies 238
Cambridge University, Imperial College London, King’s College London, Queen Mary University London, University College London and Oxford University Enter into Research and Development Agreement with Pfizer 239
EMD Serono Enters Into Research Agreement With Pfizer And Broad Institute 241
BioRestorative Therapies Enters into Research Agreement with Pfizer 242
Process Systems Enters Into Co-Development Agreement With Pfizer 243
Pfizer Enters Into Development Agreement With University of Texas MD Anderson Cancer Center For Cancer Immunotherapy 244
Octapharma Enters Into Co-Marketing Agreement With Pfizer 245
Protagen Enters Into Biomarker Discovery Agreement With Pfizer 246
Eli Lilly Enters Into Co-Development Agreement With Pfizer For Tanezumab 247
Joslin Diabetes Center Enters Into Co-Development Agreement With Pfizer And Lilly 248
Sanford-Burnham Medical Research Institute Enters Into Research Agreement With Pfizer 249
Pfizer Plans To Form Joint Ventures To Accelerate Drug Development 250
Centers For Therapeutic Innovation Partners with UC San Francisco 251
Merck Enters Into Co-Development Agreement With Pfizer For Ertugliflozin 252
Anacor Pharma Amends Research Agreement With Bill & Melinda Gates Foundation 253
Bind Therapeutics Enters Into Global Agreement With Pfizer To Develop And Commercialize Multiple Accurins 254
OxOnc Development Enters Into Co-Development Agreement With Pfizer For Crizotinib 255
Humedica Enters Into Agreement With Pfizer 257
AstraZeneca And Pfizer Partner With Government of Quebec To Develop Research Centre 258
Cystic Fibrosis Foundation Therapeutics Enters Into Research Agreement With Pfizer For Cystic Fibrosis Drugs 259
Apredica Enters Into Research Agreement With Pfizer 260
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.